Hüseyin Sina Coşkun, Furkan Erdoğan, Hikmet Çinka, Nevzat Dabak

Extra-abdominal desmoid fibromatosis: An evaluation of clinical factors affecting local recurrence rates

Objective: The aim of this study was to determine the prognostic factors for recurrence in patients with extra-abdominal desmoid tumors (EDTs) treated surgically. Methods: This single-institution, retrospective study included patients with a histologically-proven extra-abdominal desmoid tumor between 2007 and 2018. The demographic characteristics (age, sex) of the patients, tumor characteristics (region, size, proximity to neurovascular structures, margins), treatment management (surgery and/or adjuvant radiotherapy), and clinical results were analyzed. The effects of these possible prognostic factors on overall and disease-free survival rates and the risk of local recurrence were evaluated. Results: Evaluation was made of 22 patients (16 females, 6 males) with a mean age at diagnosis of 34.7 years (range = 22-76 years). The mean follow-up was 104 months (range = 4.8-168). Tumor localization was in the upper extremity in 4 patients (18.1%), the lower extremity in 11 (50.0%), and the trunk in 7 (31.8%). The mean tumor size (maximum diameter) was 5.2 cm (range = 0.6-13 cm; median = 5.8 cm), and the mean tumor volume was 181.3 ± 531.4 ml. All the 22 patients were treated surgically along with adjuvant radiotherapy (RT) administered to 8 in addition to surgery for the primary treatment of the tumor. Following primary surgery, resection margins were R0 in 11 patients, R1 in 9 and R2 in 2. Local recurrence (LR) developed in 6 patients (27.2%) during the follow-up period. Recurrence-free survival rate (RFS) was 90.9% at one year, 74.1% at 5 years, and 61.7% at 10 years. During the follow-up, no patient died, and distant metastasis was not detected. Tumor length, resection margins, and adjuvant RT were observed to influence the risk of local recurrence (P < 0.05). Conclusion: The results of this study have demonstrated that tumor size ≥ 5 cm and the presence of microscopic or macroscopic positive surgical margins can increase the risk of LR, and adjuvant RT can reduce the development of LR in the management of EDT

PDF

___

1. Papagelopoulos PJ, Mavrogenis AF, Mitsiokapa EA, et al. Current trends in the management of extra-abdominal desmoid tumours. World J Surg Oncol. 2006;4 (1):1-8. 10.1186/1477-7819-4-21
2. Micke O, Seegenschmiedt MH. German Cooperative Group on Radiotherapy for Benign Diseases. Radiation therapy for aggressive fibromatosis (desmoid tumors): Results of a national patterns of care study. Int J Radiat Oncol Biol Phys. 2005;61(3):882-891. 10.1016/j.ijrobp.2004.07.705
3. Kasper B, Baumgarten C, Bonvalot S, et al. Management of sporadic desmoid- type fibromatosis: A European consensus approach based on patients’ and professionals’ expertise–a sarcoma patients EuroNet and European Organisa- tion for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group initiative. Eur J Cancer. 2015;51(2):127-136. 10.1016/j.ejca.2014.11.005
4. De Bree E, Keus R, Melissas J, et al. Desmoid tumors: Need for an individualized approach. Expert Rev Anticancer Ther. 2009;9(4):525-535. 10.1586/era.09.9 5. Pajares B, Torres E, Jiménez B, et al. Multimodal treatment of desmoid tumours: The significance of local control. Clin Transl Oncol. 2011;13(3):189-193. 10. 1007/s12094-011-0639-4
6. Kasper B, Ströbel P, Hohenberger P. Desmoid tumors: Clinical features and treatment options for advanced disease. Oncology. 2011;16(5):682. 10.1634/ theoncologist.2010-0281
7. Ilaslan H, Schils J, Joyce M, et al. Radiofrequency ablation: Another treatment option for local control of desmoid tumors. Skelet Radiol. 2010;39(2):169-173. 10.1007/s00256-009-0807-6
8. Briand S, Barbier O, Biau D, et al. Wait-and-see policy as a first-line manage- ment for extra-abdominal desmoid tumors. JBJS. 2014;96(8):631-638. 10.2106/ JBJS.M.00988
9. Salas S, Dufresne A, Bui B, et al. Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: A wait-and-see policy according to tumor presentation. J Clin Oncol. 2011;29(26):3553-3558. 10.1200/JCO.2010.33.5489
10. Stoeckle E, Coindre JM, Longy M, et al. A critical analysis of treatment strate- gies in desmoid tumours: A review of a series of 106 cases. Eur J Surg Oncol. 2009;35(2):129-134. 10.1016/j.ejso.2008.06.1495
11. Mullen JT, DeLaney TF, Kobayashi WK, et al. Desmoid tumor: Analysis of prognostic factors and outcomes in a surgical series. Ann Surg Oncol. 2012;19 (13):4028-4035. 10.1245/s10434-012-2638-2
12. Van Broekhoven DL, Verhoef C, Grunhagen DJ, et al. Prognostic value of CTNNB1 gene mutation in primary sporadic aggressive fibromatosis. Ann Surg Oncol. 2015;22(5):1464-1470. 10.1245/s10434-014-4156-x
13. Crago AM, Denton B, Salas S, et al. A prognostic nomogram for prediction of recurrence in desmoid fibromatosis. Ann Surg. 2013;258(2):347-353. 10.1097/ SLA.0b013e31828c8a30
14. Baumert BG, Spahr MO, von Hochstetter A, et al. The impact of radiotherapy in the treatment of desmoid tumours. An international survey of 110 patients. A study of the Rare Cancer Network. Radiat Oncol. 2007;2(1):12. 10.1186/1748- 717X-2-12
15. Nishida Y, Hamada S, Kawai A, et al. Risk factors of local recurrence after surgery in extraabdominal desmoid-type fibromatosis: A multicenter study in Japan. Cancer Sci. 2020;111(8):2935-2942. 10.1111/cas.14528
16. Mueller C, Croner R, Klein P, et al. Primary and recurrent sporadic desmoids: Prognostic factors influencing recurrence-free survival after complete gross resection. Int J Surg. 2016;31:63-70. 10.1016/j.ijsu.2016.05.068
17. Peng PD, Hyder O, Mavros MN, et al. Management and recurrence patterns of desmoids tumors: A multi-institutional analysis of 211 patients. Ann Surg Oncol. 2012;19(13):4036-4042. 10.1245/s10434-012-2634-6
18. Zeng WG, Zhou ZX, Liang JW, et al. Prognostic factors for desmoid tumor: A surgical series of 233 patients at a single institution. Tumor Biology. 2014;35 (8):7513-7521. 10.1007/s13277-014-2002-1
19. He XD, Zhang YB, Wang L, et al. Prognostic factors for the recurrence of sporadic desmoid-type fibromatosis after macroscopically complete resection: Analysis of 114 patients at a single institution. Eur J Surg Oncol. 2015;41 (8):1013-1019. 10.1016/j.ejso.2015.04.016
20. Kim Y, Rosario MS, Cho HS, et al. Factors associated with disease stabilization of desmoid-type fibromatosis. Clinics in Orthopedic Surgery. 2020;12(1):113. 10.4055/cios.2020.12.1.113
21. Van Broekhoven DLM, Verschoor AJ, van Dalen T, et al. Outcome of nonsurgi- cal management of extra-abdominal, trunk, and abdominal wall desmoid-type fibromatosis: A population-based study in the Netherlands. Sarcoma. 2018;2018:5982575. 10.1155/2018/5982575
22. Saltiel S, Bize PE, Goetti P, et al. Cryoablation of extra-abdominal desmoid tumors: A single-center experience with literature review. Diagnostics. 2020;10 (8):556. 10.3390/diagnostics10080556
23. Ballo MT, Zagars GK, Pollack A, et al. Desmoid tumor: Prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy. Am J Clin Oncol. 1999;17(1):158-158. 10.1200/JCO.1999.17.1.158
24. Huang K, Fu H, Shi YQ, et al. Prognostic factors for extra‐abdominal and abdominal wall desmoids: A 20‐year experience at a single institution. J Surg Oncol. 2009;100(7):563-569. 10.1002/jso.21384
25. Milos RI, Moritz T, Bernathova M, et al. Superficial desmoid tumors: MRI and ultrasound imaging characteristics. Eur J Radiol. 2015;84(11):2194-2201. 10. 1016/j.ejrad.2015.08.012
26. Nuyttens JJ, Rust PF, Thomas CR, et al. Surgery versus radiation therapy for patients with aggressive fibromatosis or desmoid tumors: A comparative re- view of 22 articles. Cancer. 2000;88(7):1517-1523. 10.1002/(SICI)1097-0142 (20000401)88:7<1517::AID-CNCR3>3.0.CO;2-9
27. Merchant NB, Lewis JJ, Woodruff JM, et al. Extremity and trunk desmoid tumors: A multifactorial analysis of outcome. Cancer. 1999;86(10):2045- 2052. 10.1002/(SICI)1097-0142(19991115)86:10<2045::AID-CNCR23>3.0. CO;2-F